1. HBW Insight

FDA Questions Constitutionality Of Proposed CIR Bridge, A Blow To CMA Bill

 
• By Lauren Nardella

The Cosmetic Modernization Amendments of 2015 is touted by small business as a more appropriately sized update to the regulatory framework than the front-running PCPSA. However, some provisions seen as vital are absent from the bill, while its call for FDA to accept CIR safety decisions could be deemed unconstitutional, an FDA official suggests in a letter to Senate HELP Committee Chair Lamar Alexander.

US Constitution

If lawmakers and industry stakeholders knuckle down in the next Congress to reach a compromise on cosmetics reform legislation, FDA’s recent exchanges with prominent Senators likely will serve as a compass to help guide discussions.

The agency offered perspective in an Oct. 17 letter to Sen. Lamar Alexander, R-Tenn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

More from HBW Insight

Beauty Industry Not Taking Advantage Of CBP’s Duty Drawback – IBA Conference

 
• By Eileen Francis

US Customs and Border Protection’s program allowing companies to recoup fees for imported goods that were destroyed or exported is applicable in the case of most of President Trump’s reciprocal tariffs. However, most cosmetic companies don’t make use of it.

Kennedy Defends Spending Cuts During Contentious Senate Hearing On HHS Budget

 
• By Elizabeth Orr

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By Tom Gallen

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.